FI920342A0 - Komplex som innehaoller koaguleringsfaktor ix och foerfarande foer framstaellning daerav. - Google Patents

Komplex som innehaoller koaguleringsfaktor ix och foerfarande foer framstaellning daerav.

Info

Publication number
FI920342A0
FI920342A0 FI920342A FI920342A FI920342A0 FI 920342 A0 FI920342 A0 FI 920342A0 FI 920342 A FI920342 A FI 920342A FI 920342 A FI920342 A FI 920342A FI 920342 A0 FI920342 A0 FI 920342A0
Authority
FI
Finland
Prior art keywords
koaguleringsfaktor
komplex
foerfarande foer
foer framstaellning
och foerfarande
Prior art date
Application number
FI920342A
Other languages
English (en)
Other versions
FI920342L (fi
FI100111B (fi
Inventor
Yendra Linnau
Original Assignee
Immuno Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuno Ag filed Critical Immuno Ag
Publication of FI920342A0 publication Critical patent/FI920342A0/fi
Publication of FI920342L publication Critical patent/FI920342L/fi
Application granted granted Critical
Publication of FI100111B publication Critical patent/FI100111B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Saccharide Compounds (AREA)
  • Measurement Of Velocity Or Position Using Acoustic Or Ultrasonic Waves (AREA)
  • Medicinal Preparation (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FI920342A 1991-01-25 1992-01-24 Hyytymistekijää IX sisältävä kompleksi ja menetelmä sen valmistamiseks i FI100111B (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0016391A AT402261B (de) 1991-01-25 1991-01-25 Komplex enthaltend den gerinnungsfaktor ix

Publications (3)

Publication Number Publication Date
FI920342A0 true FI920342A0 (fi) 1992-01-24
FI920342L FI920342L (fi) 1992-07-26
FI100111B FI100111B (fi) 1997-09-30

Family

ID=3483232

Family Applications (1)

Application Number Title Priority Date Filing Date
FI920342A FI100111B (fi) 1991-01-25 1992-01-24 Hyytymistekijää IX sisältävä kompleksi ja menetelmä sen valmistamiseks i

Country Status (12)

Country Link
US (2) US5281661A (fi)
EP (1) EP0496725B1 (fi)
JP (2) JP2651307B2 (fi)
AT (2) AT402261B (fi)
CA (1) CA2059979C (fi)
CZ (2) CZ280297B6 (fi)
DE (1) DE59207638D1 (fi)
DK (1) DK0496725T3 (fi)
ES (1) ES2098485T3 (fi)
FI (1) FI100111B (fi)
HU (1) HU212362B (fi)
SK (2) SK280130B6 (fi)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69231401T2 (de) 1991-03-01 2001-02-08 Rhone-Poulenc Rorer International (Holdings) Inc., Greenville Herstellung von faktor-ix
DE4342132C1 (de) * 1993-12-10 1994-11-03 Octapharma Ag Verfahren zur Herstellung virusinaktivierte Vitamin K abhängige Plasmakomponenten sowie Protein C und Protein S enthaltender Mittel durch Membran-Chromatographie
DE69523722T2 (de) 1994-06-30 2002-08-01 Dade Behring Inc., Deerfield Bioaktive poröse trennteile
US5888826A (en) * 1994-06-30 1999-03-30 Dade Behring Inc. Combination reagent holding and test device
US5602037A (en) * 1994-06-30 1997-02-11 Dade International, Inc. Combination reagent holding and test device
DE19506633A1 (de) * 1995-02-25 1996-08-29 Octapharma Ag Verfahren zur Herstellung von Faktor IX aus biologischen Quellen
US5714583A (en) 1995-06-07 1998-02-03 Genetics Institute, Inc. Factor IX purification methods
US5958716A (en) * 1996-06-06 1999-09-28 Dade Behring Inc. Blood factor assay
CA2308610A1 (en) * 1997-11-05 1999-05-14 Welfide Corporation Heparin cofactor ii preparation and process therefor
WO2005033140A1 (ja) * 2003-09-30 2005-04-14 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute 高純度血液凝固ｉｘ因子調製物およびその精製方法
CA2571292C (en) * 2004-06-30 2013-05-21 Nektar Therapeutics Al, Corporation Polymer-factor ix moiety conjugates
EP2360171A1 (en) 2004-12-23 2011-08-24 Novo Nordisk Health Care AG Reduction of the content of protein contaminants in compositions comprising a vitamin K-dependent protein of interest
TWI445714B (zh) 2009-05-27 2014-07-21 Baxter Int 產製用於皮下使用之高濃度免疫球蛋白製備物之方法
HUE028832T2 (en) 2009-09-17 2017-01-30 Baxalta Inc Stable co-formulation of hyaluronidase and immunoglobulin, as well as a process for its preparation
US20120076779A1 (en) 2010-09-17 2012-03-29 Baxter Healthcare S.A. STABILIZATION OF IMMUNOGLOBULINS AND OTHER PROTEINS THROUGH AQUEOUS FORMULATIONS WITH SODIUM CHLORIDE AT WEAK ACIDIC TO NEUTRAL ph
SG191186A1 (en) 2010-12-15 2013-07-31 Baxter Int Eluate collection using conductivity gradient
WO2012154272A1 (en) 2011-02-25 2012-11-15 Wellstat Diagnostics, Llc Assays for detecting enzymatic activity
WO2025068923A2 (en) 2023-09-26 2025-04-03 Takeda Pharmaceutical Company Limited IMMUNOGLOBULIN FORMULATIONS DEPLETED IN IgA

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2543448A1 (fr) * 1983-04-01 1984-10-05 Rhone Poulenc Spec Chim Procede de fractionnement du plasma
US4820805A (en) * 1983-07-14 1989-04-11 New York Blood Center, Inc. Undenatured virus-free trialkyl phosphate treated biologically active protein derivatives
AT389815B (de) * 1984-03-09 1990-02-12 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
US4721572A (en) * 1985-07-12 1988-01-26 Miles Laboratories, Inc. Purfication of blood clotting factors and other blood proteins on non-carbohydrate sulfated matrices
ATE130620T1 (de) * 1986-01-06 1995-12-15 Blood Systems Inc Therapeutisches blutprodukt, mittel und verfahren zu dessen erzeugung.
JPS63108000A (ja) * 1986-05-15 1988-05-12 Green Cross Corp:The 第８因子の精製方法
US4725673A (en) * 1986-08-29 1988-02-16 Alpha Therapeutic Corporation Plasma fraction purification using silica resin bound to a ligand
EP0317376B2 (fr) * 1987-10-23 1996-04-03 Centre Regional De Transfusion Sanguine De Lille Préparation de concentré de facteur IX humain de haute pureté et d'autres protéines plasmatiques
DE3914869C1 (fi) * 1989-05-05 1990-08-09 Biotest Pharma Gmbh, 6072 Dreieich, De

Also Published As

Publication number Publication date
SK280989B6 (sk) 2000-10-09
JP2651307B2 (ja) 1997-09-10
JPH08259449A (ja) 1996-10-08
FI920342L (fi) 1992-07-26
AT402261B (de) 1997-03-25
FI100111B (fi) 1997-09-30
HUT63863A (en) 1993-10-28
CZ280725B6 (cs) 1996-04-17
DK0496725T3 (da) 1997-06-09
ATE146220T1 (de) 1996-12-15
EP0496725A3 (en) 1993-05-05
HU212362B (en) 1996-06-28
EP0496725A2 (de) 1992-07-29
CZ154794A3 (en) 1996-04-17
ES2098485T3 (es) 1997-05-01
JP2866047B2 (ja) 1999-03-08
CS21192A3 (en) 1992-08-12
HU9200225D0 (en) 1992-04-28
CA2059979A1 (en) 1992-07-26
SK280130B6 (sk) 1999-08-06
US5409990A (en) 1995-04-25
EP0496725B1 (de) 1996-12-11
CA2059979C (en) 2003-04-15
DE59207638D1 (de) 1997-01-23
JPH04295432A (ja) 1992-10-20
US5281661A (en) 1994-01-25
ATA16391A (de) 1996-08-15
CZ280297B6 (cs) 1995-12-13

Similar Documents

Publication Publication Date Title
FI920342A0 (fi) Komplex som innehaoller koaguleringsfaktor ix och foerfarande foer framstaellning daerav.
SE8206168D0 (sv) Preparations and process for preparation thereof
DE3873337D1 (de) Aetzverfahren mittels gasplasma.
DE59009451D1 (de) Colestyramin als lipidsenker enthaltende präparate.
ES2109254T3 (es) Proteinas antigenas y vacunas que las contienen para la prevencion de cocidiosis.
FI862882L (fi) 1-substituerade oxindol-3 -karboxiamider som antiinflammatoriska och vaerkstillande medel.
NO982874L (no) Farmasöytiske preparater med vitamin D-analoger
DE69927602D1 (de) Verfahren zur herstellung von vitaminpulvern
DK198785A (da) 2-amino-3-ethoxycarbonylamino-6-(p-fluor-benzylamino)-pyridin-gluconatog farmaceutiske praeparater som indeholder dette stof
ATE276357T1 (de) Reinigung von vitamin-k abhaengigen proteinen durch membrane chromatographie
DK188286A (da) Phenylalkyl-2,3-dihydrobenzofuraner og analoge heraf samt praeparater indeholdende disse forbindelser
FI103178B1 (fi) Menetelmä vaikuttavaa ainetta sisältävien vesipohjaisten liposomisuspensioiden valmistamiseksi
GR880100869A (el) Μέ?οδος παρασκευής παραγώγων υποκατεστημένου στυρολίου.
ES2101334T3 (es) Utilizacion terapeutica de la fosforil-l-serina-n-acil-esfingosina.
DK1001942T3 (da) Polyhydroxybutylpyraziner, deres fremstilling samt medikamenter indeholdende disse forbindelser
TR25423A (tr) DAHA AKTIF TüRLERI BAKIMINDAN ZENGINLESTIRILMIS SIPERMETRIN VEYA SIFLUTRIN ISOMERLERININ KARISIMLARININ HAZIRLANMASI.
ATE33389T1 (de) Derivat eines ethers von n-propanolamin.
DK319384A (da) 1-0-alkyl-3-amino-propan-1,2-diol-2-0-phospholipider, fremgangsmaade til deres fremstilling samt farmaceutiske praeparater indeholdende disse
MX9102087A (es) Complejos que contienen acidos s(+) fenilalcanos y acidos alfa-hidroxi alcanos.
SE8002244L (sv) Nytt 1alfa,25-dihydroxi-cholekalciferolderivat, sett for framstellning samt anvendning derav som lekemedel och farmaceutiska kompositioner inehallande denna forening
JPS5291026A (en) Method of forming quinacridone beta-crystals
IT8321507A0 (it) Procedimento di preparazione fermentativa di l-leucina.
JPS5234981A (en) Production of alcohol from cellulose
DE59610098D1 (de) Protein mit anti-tumorwirkung
FI852537A0 (fi) Foerfaranden och medel vid biologisk behandling.